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Abstract
Background: In many developing countries, out-of-pocket payment remains a primary mechanism
by which patients infected with HIV access treatment. In India, this has been changing as the
National AIDS Control Organization (NACO) has been rolling out free antiretroviral therapy
throughout the country since 2004. The vast majority of patients, however, remain without access
to free medicines.
Methods: A retrospective chart review was performed on data obtained from a registry of ninety-
three (93) patients attending a self-pay clinic at the All India Institute of Medical Sciences in Delhi,
India. Multivariable Cox proportional hazard and logistic regression models were explored to
assess the relationship between lost-to-follow-up status and the predictor variables: age, sex,
household income, baseline CD4 count, and distance from clinic.
Results: Lost-to-follow-up rates were very high; 68% (63/93) were lost-to-follow-up till the time
of chart review, including 59% (55/93) who were lost within one year. In both regression models,
younger age, low baseline CD4 counts, and low income level were significantly associated with
increased risk of lost-to-follow-up. Additionally, there was a significant interaction between income
and CD4 counts. The patients with both low CD4 counts and low income level were more likely
to be lost-to-follow-up than would be predicted by each covariable alone.
Conclusion: In this small cohort of AIDS patients attending a self-pay antiretroviral clinic at a large
tertiary care center in Delhi, India, follow-up rates were quite poor. Poorer patients tended to
present to clinic with more depressed CD4 counts and were less likely to be retained in care.
These findings indicate that greater strides must be taken to improve the recruitment and retention
of poor patients. The expansion of free antiretrovirals is one step among many necessary to achieve
this objective.
Introduction
Since April 2004, the National AIDS Control Organiza-
tion (NACO) has been funding medications and services
to be delivered through free antiretroviral (ARV) clinics
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throughout India[1]. This has been a welcome change for
the approximately five million Indians already living with
HIV/AIDS[2], many of whom now have a possibility of
accessing life-saving medications. Previously, only
patients with financial resources to pay, had access to ARV
services mostly through India's largely unregulated private
sector, where more than 75% of all healthcare expendi-
tures take place[3]. Patients additionally could receive
ARV services through a limited number of tertiary care
government hospitals where consultation was available at
subsidized prices but where medication costs were to be
born by patients; other patients did not receive services.
For many patients in rural areas or in states where free
ARVs have been slow to come, this still remains the real-
ity. Additionally, many laboratory services and other med-
ications necessary for comprehensive AIDS care are not
available for free.
NACO originally focused their resources on the six high-
prevalence states of Andhra Pradesh, Karnataka, Mahar-
ashtra, Tamil Nadu, Manipur, and Nagaland, as well as
the national capital territory and seat of NACO, Delhi.
Since then, ARV roll-out has been expanding to other
lower-prevalence states with more concentrated epidem-
ics. Owing to logistical concerns over distributing ARVs
and providing care in more rural areas, much of the ARV
roll-out has focused on urban centers associated with
large government hospitals. While this has advantages, for
example, in greater ease of access to laboratory services,
this has made access to care challenging, if not impossible,
for some patients, especially among rural or sub-urban
poor patients. Even in the era of free ARVs in India, many
patients must use significant financial resources to pay for
their care.
Very few studies to date have assessed follow-up rates
among patients living with HIV/AIDS in India. One eth-
nographic study among patients in Chennai, Tamil Nadu
(southern India) highlighted the extreme measures that
patients often take – selling personal and family property,
for example – to cover the costs of medicines. Among the
sixty patients investigated, thirty-two percent reported
having taken a self-imposed drug holiday owing to finan-
cial difficulties[4]. Another study by the same group of
researchers, but among a different cohort of three-hun-
dred patients from Chennai, reported high levels of adher-
ence, although cost was the most common cause of non-
adherence (32%)[5].
To examine the challenges of fee-for-service AIDS care in
the northern Indian context, we undertook a retrospective
chart review of a small cohort of patients attending a self-
pay outpatient clinic at the All-India Institute of Medical
Sciences (AIIMS), a tertiary care center in Delhi. This was
done during the transition period from self-pay to free
ARVs, following the designation of AIIMS as a new NACO
free ARV center. This analysis was thus undertaken as a
way to assess the challenges of the self-pay system, both to
examine how the new clinic structure might address these
issues and to inform the public health issues in the many
areas where free ARVs have yet to arrive.
The variables that were available for analysis included:
age, sex, distance from clinic, household income, and
CD4 count at ARV initiation. We hypothesized that lower
CD4 count as an indicator of more advanced disease,
lower household income as an indicator of poverty level,
and distance from clinic as an indicator of a barrier to
access would be associated with increased risk of the
patients' lost-to-follow-up.
Methods
We retrospectively reviewed the charts of all HIV-infected
patients (n = 93) treated with antiretrovirals at the AIIMS
clinic during the years 2001 to 2004. AIIMS is a large ter-
tiary care government hospital in India's capital city, and
caters to a wide variety of patients from all socioeconomic
backgrounds. Although medical care and consultations
are typically provided for free or at low cost, most medica-
tions are obtained by patients at market prices. This was
the case during the duration of the study period; the study
period ceased following the introduction of the new
NACO-sponsored free ARV clinic. Patients were initiated
on ARVs if their CD4 counts were less than 200 cells/
microliters, if they had AIDS-defining illnesses, or at the
discretion of the senior physician.
At intake, clinic staff administered a questionnaire to
probe their demographic background, prior medical treat-
ment, and HIV risk. This included monthly household
income ("household income") and time in hours it took
to reach the clinic by available mode of transportation
("distance from clinic"). The nurse practitioner also took
responsibility for consenting and counseling the patients,
and monitoring their medications.
Patients were referred from various disciplines within
AIIMS or health care providers outside AIIMS, even from
other states. Regimens were typically nevirapine and lam-
ivudine, with either stavudine (80%) or zidovudine (8%);
the remaining patients were on efavirenz-based regimens,
with lamivudine and either zidovudine or stavudine; one
patient received nevirapine with indinavir and zidovu-
dine. All patients received baseline CD4 measurements.
Owing to cost, CD4 counts were not consistently available
at follow-up. Lost-to-follow-up was defined by missing at
least two monthly appointments and never returning to
clinic. As patients were typically not followed by phone or
mail, the clinical team was unaware of what happened to
such patients.International Journal for Equity in Health 2007, 6:14 http://www.equityhealthj.com/content/6/1/14
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Data analysis was conducted with SAS version 9.1 (Carey
Institute, North Carolina, USA). All statistical tests were
assessed at an alpha = 0.05 level. All patients started on
ARVs had baseline CD4 counts that could be used as inde-
pendent predictor variables. Owing to the lack of CD4
counts or HIV viral loads available at follow-up, neither of
these could serve as outcomes variables. As such, survival
analysis was performed with time-to-failure calculated
from the time when patients started HAART to the time
when they were lost to follow-up or were censored (owing
to the start of the new free clinic), rounded to the nearest
month. A Cox proportional hazards multiple regression
model was attempted to fit the data using the demo-
graphic variables as well as baseline CD4 count. There
were five patients for whom income data was not availa-
ble; for these patients, the overall mean income level was
given (i.e., their centered income was set to 0). The pro-
portionality assumption was tested by assessing for signif-
icance of the time-dependent covariables (using the
natural logarithm of time). During the model building
process, the log-likelihood ratio (deviance) was used to
compare two models and decide whether a variable
should be kept or dropped.
To check the findings of this analysis, a multivariable
logistic model was attempted to fit the same data, compar-
ing patients who were lost to follow-up versus those who
were retained in care through the opening of the new ARV
clinic. Preliminary bivariable analyses between outcome
and predictors were undertaken using two-tailed Fisher's
exact test for categorical variables and independent sam-
ples t-test for continuous variables. Pearson's correlation
coefficients were used to make pair-wise comparisons
between predictor variables.
All odds ratios and hazards ratios were adjusted to the
units of the variable in question for ease in interpretation
(per 25 cells/microliter for CD4, per 500 Rs for income,
and per 5 hours for distance from clinic). Note that this
does not alter significance testing, only interpretability of
the resulting odds ratios and hazard ratios.
Results
Basic demographic characteristics are shown in table 1.
For those patients for whom counts were available at 6
months follow-up (n = 25), the median CD4 increase was
159 cells/microliter (Interquartile Range 34 to 254).
Owing to the small number of patients with follow-up
laboratory data, no further analyses were undertaken on
follow-up CD4 counts. Following ARV initiation, 63 of 93
(68%) missed at least two appointments and never
returned. A total of 55 patients were lost within 12
months or less, including 11 patients who did not return
after their first post-ARV-initiation visit. Patients came not
only from Delhi (n = 31) but also from several neighbor-
ing states, most prominently Utter Pradesh (n = 21), Har-
yana (n = 16), Bihar (n = 15), states with varying levels of
low health infrastructure. Women tended to live closer to
the clinic than men, though not significantly so (4.32 ver-
sus 7.16 hours, p-value = 0.11). Age, income, distance
from clinic, and CD4 count were all significantly associ-
ated with lost-to-follow-up in preliminary bivariable anal-
yses (table 2). The survival curve for the whole sample,
assessing time to lost-to-follow-up (LTFU), shows a rapid
decline within the first year following ARV initiation (Fig-
ure 1). Income, distance from clinic, and CD4 count at
baseline were highly correlated; in multivariable analyses,
we thus corrected for this by centering these variable
around the mean.
Table 2: Bivariable analysis of predictor variables
Characteristic Continued Care (N = 30) Lost to Follow Up (N = 63) P-Value
Age in years, Mean +/- SD 37.2 +/- 9.2 33.0 +/- 7.1 0.04
Sex, females, n (%) 7 (23.3%) 12 (19%) 0.78
Distance from clinic in hours, Mean +/- SD 4.2 +/- 5 7.7 +/- 8.8 0.02
Monthly Household Income in Rs and $, Median (IQR) Rs.5000 (3000 to 5500) US$114 (68 to 125) Rs.2500 (2000 to 3500) US$57 (45 to 80) 0.0006
Median CD4 Count at ARV initiation in cells/µL (IQR) 129.5 (67.0 to 179.0) 72 (41 to 129) 0.005
Median Time of Follow-Up in Months (IQR) 33.9+/-15.5 7+/-8.4 <0.0001
Table 1: Characteristics of patients receiving ARVs at AIIMS self-pay clinic (n = 93)
Characteristic Value
Age in years, Mean +/- SD 34.4 +/- 8.0
Sex, females, n (%) 19 (20.4%)
Distance from clinic in hours, Mean +/- SD 6.5 +/- 7.9
Monthly Household Income in Rs and $, Median (IQR) Rs.3000 (2500 to 5000)
US$68 (56.8 to 113.6)
Median CD4 Count at ARV initiation in cells/µL (IQR) 83 (57 to 146)
Median Time of Follow-Up in Months (IQR) 8 (3 to 22)International Journal for Equity in Health 2007, 6:14 http://www.equityhealthj.com/content/6/1/14
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For the Cox mulitivariable regression, the proportional
hazards assumption was violated only for the variable of
CD4 counts at baseline (Deviance = 4.9, p-value = 0.03).
As such, this variable was retained in the model, whereas
the other demographic variables were dropped, since
there was neither a plausible explanation for time-
dependence nor did any of their parameter estimates
approach significance. To further explore the relationship
between the main effects, second-order interaction terms
were thus added in the model. The only interaction term
found to be significant was that between CD4 count at
baseline and income (LR difference = 9.8, p-value =
0.002). The final result of this model building process is
shown in Table 3.
To confirm these results, a multivariable logistic regres-
sion model was developed; as before, the log likelihood
ratio was used to compare models in a forward stepwise
fashion. In the multivariable regression case, the interac-
tion term between CD4 count at baseline and income did
not reach significance (Deviance = 1.8, p-value = 0.16).
However, this term was kept in the model for comparabil-
ity. The final results are shown in Table 4. Again, income
and age were significant predictors of lost-to-follow-up
status, as was the CD4-by-income interaction.
Discussion
In this small cohort of geographically-diverse patients
receiving self-pay HIV care at a tertiary care center in
northern India, high lost-to-follow-up rates were seen. In
multivariable Cox and logistic regression models, we
found that lost-to-follow-up patients were younger in age,
had lower CD4 counts at presentation, and had lower
monthly incomes. An interaction term between income
and baseline CD4 count was significant in both models.
This suggests that poorer patients initiated ARV therapy at
a more progressed disease state, and when they did enter
care, they tended not to be retained in care. The interac-
tion term suggests that poorer patients with lower CD4
counts had worse follow-up rates than would be predicted
by their CD4 counts and income levels alone. That is, the
model of healthcare delivery that was being undertaken at
that time was least effective for the most sick and poor
patients.
Table 4: Odds ratios for logistic regression model
Main Effects Model
Variable OR (95% Confidence Interval) p-value
Age 0.94 (0.88 to 1) 0.02
Sex 0.87 (0.26 to 2.96) 0.71
Monthly income 0.82 (0.71 to 0.95) 0.004
Distance from clinic 1.06 (0.72 to 1.56) 0.92
Baseline CD4 Count 0.79 (0.64 to 0.98) 0.11
Model Including Interaction Terms
Variable OR (95% Confidence Interval) p-value
Age 0.92 (0.86 to 0.99) 0.02
Sex 0.77 (0.21 to 2.9) 0.71
Monthly income 0.76 (0.63 to 0.92) 0.004
Distance from clinic 0.98 (0.66 to 1.46) 0.92
Baseline CD4 Count 1.80 (0.87 to 3.7) 0.11
CD4 * Income Interaction 0.89 (0.81 to 0.99) 0.03
Note: Hazard Ratios represent the increased relative risk associated 
with a unit increase in the covariate; for age, 1 year; for monthly 
income, 500 Rs; for distance from clinic, 5 hours; for CD4 counts, 25 
cells/microliter.
Survival function time-to-LTFU Figure 1
Survival function time-to-LTFU.
Table 3: Hazard ratios for cox regression model
Main Effects Model
Variable HR (95% Confidence Interval) p-value
Age 0.96 (0.93 to 1) 0.02
Sex 0.82 (0.42 to 1.6) 0.71
Monthly income 0.89 (0.82 to 0.97) 0.004
Distance from clinic 1.00 (0.96 to 1.16) 0.92
Baseline CD4 Count 0.91 (0.8 to 1.03) 0.11
Model Including Interaction Terms
Variable HR (95% Confidence Interval) p-value
Age 0.96 (0.93 to 0.99) 0.02
Sex 0.90 (0.46 to 1.76) 0.71
Monthly income 0.86 (0.79 to 0.94) 0.004
Distance from clinic 0.99 (0.95 to 1.02) 0.92
Baseline CD4 Count 1.49 (1.11 to 2.01) 0.11
CD4 * Time Interaction 0.91 (0.81 to 1.04) 0.03
CD4 * Income Interaction 0.94 (0.9 to 0.99) 0.01
Note: Hazard Ratios represent the increased relative risk associated 
with a unit increase in the covariate; for age, 1 year; for monthly 
income, 500 Rs; for distance from clinic, 5 hours; for CD4 counts, 25 
cells/microliter.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Journal for Equity in Health 2007, 6:14 http://www.equityhealthj.com/content/6/1/14
Page 5 of 5
(page number not for citation purposes)
Although women constitute approximately half of the
Indian epidemic, the clinic only recruited 20% women.
While this study cannot directly address this issue, it is
likely due to their limited mobility compared to men.
Indeed, those women who did come into care tended to
live farther away from the clinic, though not significantly
so. Further studies should address this issue, although it is
fairly intuitive that local provision of care should improve
both recruitment and outcomes of HIV-positive women.
The most prominent limitations of this study are its retro-
spective nature, its small sample size, and the high vari-
ances inherent in collecting social data like income and
distance from clinic. Few generalizations should be made
from these preliminary results. Additionally, per capita
income of the patient would have been a more useful
indicator of economic status than household income.
Unfortunately, we did not collect the data in a way that
could assess this; as such, the association of economic sta-
tus and poor follow-up must be considered tentative.
On the whole, however, our results do suggest that ARV
delivery methods in India must be improved to ensure
good patient outcomes and ward off drug resistance.
Excellent results have been demonstrated in resource-
poor settings, including India, with decentralized, locally-
provided care with strong social support and community
healthworkers [5-8]. Even in this cohort, the improve-
ments in CD4 counts for the small number of patients for
whom these were available at 6 month follow-up were
consistent with other studies[9]. Private providers will
continue to play an important role in the Indian health
system[10], and engaging such providers to deliver high-
quality care to poor patients is central to improving
equity[11,12]. Financing mechanisms to decrease finan-
cial burden on patients are feasible in developing coun-
tries[13]. Such mechanisms must serve to better recruit
and retain poorer patients into AIDS care and treatment.
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